NanoViricides, Inc. (NYSE American: NNVC) has initiated patient enrollment and dosing in its Phase II clinical trial of NV-387 Oral Gummies for the treatment of Bundibugyo Ebolavirus and other Ebola viruses, the company announced. The trial is taking place at an Ebola Treatment Center in the Ituri province of the Democratic Republic of Congo (DRC), a region that has experienced recurrent Ebola outbreaks.
The Phase IIA portion of the study began enrollment and dosing around September 23, according to the company. This stage is designed to establish a safe and well-tolerated dosing protocol for NV-387. The resulting protocol will then be used in the Phase IIB portion, which will evaluate the drug’s safety, tolerability, and effectiveness. The trial is registered in the Pan African Clinical Trials Registry under identification number PACTR202608748555077.
The news matters because Ebola remains a highly lethal viral disease with limited treatment options, particularly in outbreak settings where rapid intervention is critical. NV-387 is a broad-spectrum antiviral candidate that NanoViricides is developing not only for Ebola but also for a range of other viral infections, including RSV, COVID-19, influenza, and MPOX. If successful, the drug could offer an oral, easy-to-administer option for combating multiple viruses.
NanoViricides is a clinical-stage company creating special purpose nanomaterials for antiviral therapy. Its novel nanoviricide class of drug candidates is based on intellectual property and technology licensed from TheraCour Pharma, Inc. The company’s lead drug candidate, NV-387, is being developed as a treatment for respiratory viral infections, MPOX/Smallpox, and measles, among others. Another advanced candidate, NV-HHV-1, targets shingles.
The company has broad, exclusive licenses for several viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza, Dengue, Japanese Encephalitis, West Nile Virus, Ebola/Marburg, and certain Coronaviruses. As with any drug development, NanoViricides notes that the path to a pharmaceutical product is lengthy and requires substantial capital, and there can be no assurance that its candidates will show sufficient effectiveness and safety for human clinical development.
Investors and stakeholders can follow the latest updates on NanoViricides in the company’s newsroom at https://ibn.fm/NNVC. The full press release is available at https://ibn.fm/qC4Hk. More information about the company is available at www.nanoviricides.com.
MissionIR, a communications platform that assists IR firms with syndicated content, distributed the announcement. MissionIR is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire, editorial syndication to 5,000+ outlets, and social media distribution to millions of followers. The platform also offers corporate communications solutions tailored to private and public companies.
